Yesterday the Food and Drug Administration (FDA) approved Spravato (esketamine) nasal spray to be us...
Intranasal esketamine—a derivative of ketamine—appears to rapidly reduce symptoms of depression, inc...
A subset of individuals 65 years or older with treatment-resistant depression who took a new oral an...
In patients with treatment-resistant depression who responded to intranasal esketamine plus an antid...
